Research Topics
Species | Miguel SanzSummaryAffiliation: University of Valencia Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicinJavier de la Serna
Hospital 12 de Octubre, Madrid, Spain
Blood 111:3395-402. 2008..These data furnish clinically relevant information that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL...
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in SpainSantiago Grau
Hospital del Mar, Barcelona, Spain
BMC Infect Dis 12:83. 2012..The perspective was that of the Spanish National Health Service (NHS)...
[Monotherapy with meropenem in febrile granulocytopenic patients]M A Sanz
Servicio de Hematologia, Hospital Universitario La Fe, Valencia
Enferm Infecc Microbiol Clin 15:69-72. 1997..Related adverse events were also similar in both groups. These studies confirm that monotherapy with meropenem is as effective as ceftazidime-containing regimens for the empiric treatment of fever in granulocytopenic patients...
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA GroupMiguel A Sanz
Hospital Universitario La Fe, Valencia, Spain
Blood 112:3130-4. 2008..04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy...
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow TransplantationM A Sanz
Hematology Service, Hospital Universitario La Fe, Valencia, Spain
Bone Marrow Transplant 39:461-9. 2007..Female recipient, a female donor to male recipient and transplants performed before 1997 were associated with decreased RI. In conclusion, HSCT still appears to have a role in APL, especially for patients in CR2...
Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemiaMiguel A Sanz
Hematology Service, University Hospital La Fe, Valencia, Spain
Oncologist 10:806-14. 2005....
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidenceMiguel A Sanz
University Tor Vertgata, Rome
Haematologica 90:1231-5. 2005....
Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trialMiguel A Sanz
Servicio de Hematologia, Hospital Universitario La Fe, Av Campanar 21, 46009 Valencia, Spain
J Antimicrob Chemother 50:79-88. 2002..The aim of this study is to evaluate the efficacy and safety of cefepime plus amikacin compared with piperacillin-tazobactam plus amikacin for initial empirical treatment of fever in adult haematology patients with severe neutropenia...
Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemiaMiguel A Sanz
Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
Blood 105:3019-25. 2005....
All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemiaMiguel A Sanz
Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
Blood 104:3490-3. 2004..This study confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of protocols using ATRA and anthracycline monochemotherapy for induction and consolidation therapy in elderly patients...
Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemiaMiguel A Sanz
Haematology Service, University Hospital La Fe, Valencia, Spain
Best Pract Res Clin Haematol 16:433-51. 2003..As for maintenance therapy, once demonstrated, the advantage of using ATRA with or without low-dose methotrexate and 6-mercaptopurine has encouraged most groups to incorporate such treatment into their protocols for APL...
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMiguel A Sanz
University Hospital La Fe, Valencia, Spain
Blood 113:1875-91. 2009..Finally, the approach to special situations is also discussed, including management of APL in children, elderly patients, and pregnant women...
FLT3 inhibition as a targeted therapy for acute myeloid leukemiaMiguel Sanz
Hematology Service, University Hospital La Fe, Valencia, Spain
Curr Opin Oncol 21:594-600. 2009....
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeMiguel A Sanz
Hospital Universitario La Fe, Valencia, Spain
Blood 115:5137-46. 2010..Registered at http://www.clinicaltrials.gov as NCT00408278...
Modern approaches to treating acute promyelocytic leukemiaMiguel A Sanz
Hematology Department, University Hospital La Fe, Avda Companar 21, Valencia, 46009 Spain
J Clin Oncol 29:495-503. 2011..In this review article, we discuss most recent advances in the treatment of patients with newly diagnosed and relapsed APL...
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA groupM A Sanz
Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain
Blood 94:3015-21. 1999..These results also suggest a minor role for cytarabine and etoposide in the treatment of newly diagnosed PML/RARalpha-positive APL patients...
Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)Miguel A Sanz
Hospital Universitario La Fe, Servicio de Hematologia, Valencia, Spain
Value Health 14:90-6. 2011..This study sought to assess the health utilities of patients with chronic ITP and to evaluate the association of change in health utility with changes in other variables, including platelet response status and bleeding events...
Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemiaMiguel A Sanz
University Hospital La Fe, Avenida Campanar 21, Valencia, Spain
Clin Lymphoma Myeloma Leuk 10:S130-4. 2010....
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA groupMiguel A Sanz
Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
Blood 103:1237-43. 2004..A risk-adapted strategy combining anthracycline monochemotherapy and ATRA for induction and consolidation therapy of newly diagnosed APL results in improved antileukemic efficacy and a high degree of compliance...
Cutaneous promyelocytic sarcoma at sites of vascular access and marrow aspiration. A characteristic localization of chloromas in acute promyelocytic leukemia?M A Sanz
Servicio de Hematologia, Hospital Universitario La Fe, Av Campanar 21, 46009 Valencia, Spain
Haematologica 85:758-62. 2000..A careful physical examination of these particular sites in the follow-up of patients at risk, as well as cutaneous biopsy and laboratory examination of suspected lesions are strongly recommended...
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groupsM A Sanz
Hospital Universitario La Fe, Valencia, Spain
Blood 96:1247-53. 2000..Blood. 2000;96:1247-1253)..
Open issues on bleeding and thrombosis in acute promyelocytic leukemiaMiguel A Sanz
Hospital Universitario La Fe, Valencia, Spain
Thromb Res 125:S51-4. 2010..In addition to reviewing the available data on the incidence, outcome and prognostic factors of bleeding and thrombosis in APL, we discuss the current consensus and controversies on the most appropriate management of these complications...
Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemiaMiguel A Sanz
Hematology Service, University Hospital La Fe, Valencia, Spain
Haematologica 90:840-5. 2005....
Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantationNoemi Puig
Hematology Service, University Hospital La Fe, Valencia, Spain
Leuk Lymphoma 48:2367-74. 2007..001). Pneumonia after ASCT is a severe complication more commonly observed in patients with myeloma and with prolonged duration of neutropenia...
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignanciesJavier de la Rubia
Hematology Service, University Hospital La Fe, Valencia, Spain
Leuk Res 26:725-30. 2002..Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity...
Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantationJ de la Rubia
Bone Marrow Transplant Unit, Hematology Service, University Hospital La Fe, Valencia, Spain
Bone Marrow Transplant 27:21-5. 2001..We consider that high-dose therapy with ASCT should be considered in those elderly patients with good performance status and without general organ impairment...
Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remissionJ de la Rubia
Bone Marrow Transplant Unit, Hematology Service, University Hospital La Fe, Valencia, Spain
Int J Hematol 80:168-73. 2004..12) and disease-free survival (60% versus 36%; P = .1) compared favorably for group B. Our study suggests that collection of PBSC after additional intensification can result in a better outcome for AML patients who undergo ABSCT...
Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institutionG F Sanz
Bone Marrow Transplantation Unit, Department of Hematology, Hospital Universitario La Fe, Av. Campanar 21, 46009 Valencia, Spain
Bone Marrow Transplant 27:693-701. 2001..These preliminary results suggest that UD-CBT may be considered a reasonable alternative in adults with CML who lack an appropriate bone marrow donor...
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignanciesG F Sanz
Bone Marrow Transplantation Unit, Department of Hematology, and Laboratory of Molecular Biology, Department of Clinical Pathology, Hospital Universitario La Fe, Spain
Blood 98:2332-8. 2001..These preliminary results suggest that UD-CBT should be considered a reasonable alternative in young adults with hematologic malignancy and no appropriate bone marrow donor...
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMAJ M Hernandez
Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
Haematologica 86:807-13. 2001..clinical and biological presenting features; 2. disease outcome...
Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante HemopoyéticoE Carreras
BMT Section, Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
Haematologica 85:530-8. 2000..To analyze the results of unrelated bone marrow transplantation (UDBMT) as treatment for chronic myeloid leukemia (CML) in Spain...
Four new cases of therapy-related acute promyelocytic leukemia after mitoxantroneI Bosca
Department of Neurology, University Hospital La Fe, Av. Campanar 21, Valencia 46009, Spain
Neurology 71:457-8. 2008
Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patientsJ Sanz
Hematology Department, Hospital Universitario La Fe, Valencia, Spain
Bone Marrow Transplant 39:555-61. 2007..Patients undergoing HSCT from unrelated donors and those who develop chronic extensive GVHD are especially predisposed for this complication...
Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selectionF Moscardo
Bone Marrow Transplant Unit, Department of Hematology, Hospital Universitario La Fe, Valencia, Spain
Bone Marrow Transplant 27:983-8. 2001..03) were statistically significant variables for the development of VOD. We conclude that CD34(+) positively selected PBSC transplantation could result in a marked reduction in the incidence of VOD after allogeneic HSCT...
Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institutionJ de la Rubia
Bone Marrow Transplant Unit, Hematology Service, University Hospital La Fe, Valencia, Spain
Bone Marrow Transplant 36:325-9. 2005..This is a promising procedure in patients with AA, resulting in a rapid hematopoietic recovery, a low transplant-related mortality, and a low incidence of GVHD...
Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocolsP Bolufer
Laboratory of Molecular Biology, Department of Clinical Pathology, Hospital Universitario La Fe, Valencia, Spain
Haematologica 86:570-6. 2001..In the light of this, the Spanish group has recently designed an external quality assessment program (EQAP) of RT-PCR detection of PML-RAR, which includes a study of sensitivity of the participating laboratories...
Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignanciesA Carral
Hematology Service. University Hospital La Fe, Valencia, Spain
Bone Marrow Transplant 29:825-32. 2002..5 x 10(6) and 4 x 10(6) CD34+ cells/kg, respectively. Our results confirm the slower HR after ABSCT in AML, and highlight the importance of progenitor cell dose in accelerating HR after ABSCT...
Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institutionS Saavedra
, Hospital Universitario La Fe, Valencia, Spain
Clin Microbiol Infect 8:725-33. 2002..A high rate of CMV infection in the early period, and death caused by multiresistant Gram-negative microorganisms in the late period, were the main findings in this series...
Response to plasma exchange and steroids as combined therapy for patients with thrombotic thrombocytopenic purpuraJ de la Rubia
Haematology Department, University Hospital La Fe, Valencia, Spain
Acta Haematol 102:12-6. 1999..The combination of PE and steroids is a well-tolerated and effective treatment of TTP, but improvements in therapy are needed to manage refractory patients...
[Monitoring of minimal residual disease with the combined detection of PML/RAR alpha and RAR alpha/PML rearrangements in acute promyelocytic leukemia]P Bolufer
Departamento de Biopatología Clínica, Hospital Universitario La Fe, Valencia
Med Clin (Barc) 114:281-5. 2000..This prompted us to perform both assays in parallel to monitor a group of APL...
Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemiaA Lopez
Hematology Department, University Hospital La Fe, Avda Campanar, 21, 46009, Valencia, Spain
Leuk Res 25:685-92. 2001....
Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?J de la Rubia
Department of Hematology, La Fe University Hospital, Valencia, Spain
Transfusion 41:106-10. 2001..Data from the appearance of RBC antibodies other than ABO in patients undergoing HPC transplantation are limited...
CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic TransplantationR Arranz
Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain
Bone Marrow Transplant 29:205-11. 2002..Regardless of CsA use, further improvement in survival was apparent with time, probably due to better skills in patient care...
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapyJose Cervera
Hospital Universitario La Fe, Avenida Campanar, 21, 46009 Valencia, Spain
Haematologica 95:424-31. 2010..The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter...
A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantationNoemi Puig
Hematology Service, University Hospital La Fe, Valencia, Spain
Int J Hematol 86:186-92. 2007..ASCT should be considered a low-risk procedure, although new therapeutic approaches for patients developing severe respiratory infections are still needed...
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapyDaniela Cilloni
Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano, Turin, Italy
Haematologica 93:921-4. 2008..WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified...
Current treatment of acute promyelocytic leukemiaFrancesco Lo Coco
Haematologica 92:289-91. 2007
Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remissionAna Cid
Haematology, Infectious Diseases and Microbiology Services, Hospital Universitario La Fe, Av. Campanar 21, 46009 Valencia, Spain
Haematologica 87:ECR03. 2002
Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expressionEva Barragan
Department of Medical Pathology, Hospital Universitario La Fe Valencia, Spain
Clin Chim Acta 395:120-3. 2008..Moreover, we compare the NPM1 results with those of WT1 expression to MRD assessment...
Recent advances in the treatment of APLMiguel A Sanz
Clinical Hematology, Hematology Service, University Hospital La Fe, Valencia, Spain 46009
Clin Adv Hematol Oncol 4:727-9. 2006
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantationNoemi Puig
Hematology Service, University Hospital La Fe, Valencia, Spain
Leuk Lymphoma 47:1488-94. 2006..The cumulative incidences of TRM were 25% in the CBV and 7% in the BEAM group (p = 0.02). CBV thus produced a higher incidence of SOS and TRM than BEAM in this series...
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemiaAnna Sureda
Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Haematologica 88:1213-20. 2003..Imatinib mesylate (STI571) is a selective inhibitor of the bcr/abl tyrosine kinase with therapeutic potential in the blast crisis (BC) of chronic myelogenous leukemia (CML)...
A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemiaZaida Garcia-Casado
Department of Hematology, Hospital Universitario La Fe, Avenida Campanar, 21, 46009 Valencia, Spain
Cancer Genet Cytogenet 168:73-6. 2006....
Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE studyMiguel A Sanz
, Hospital Universitario La Fe, Valencia, Spain
Curr Med Res Opin 21:645-55. 2005..CONCLUSIONS: The clinical effectiveness of I/C was similar to that of P/T+A. In both treatment groups toxicity was low and did not limit antibiotic therapy. Resource consumption was lower with I/C...
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA GroupJuan J Ortega
, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
J Clin Oncol 23:7632-40. 2005....
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive modelPau Montesinos
Hematology Service, Hospital Universitario La Fe, Avenida Campanar 21, 46019, Valencia, Spain
Haematologica 93:67-74. 2008....
Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemiaIsabel Moreno
Molecular Biology Laboratory (Dept. Medical Pathology, Hospital Universitario La Fe, Valencia, Spain
Haematologica 88:19-24. 2003..Because of the high prevalence of these mutations within the intermediate-risk group, their detection could be useful to identify patients with a poor prognosis...
[Current indications for voriconazole in onco-hematological patients]Isidro Jarque
Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain
Rev Iberoam Micol 24:213-6. 2007..It should be kept in mind the possibility of breakthrough IFI, particularly zygomycosis, in patients treated with voriconazole for long periods...
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson
Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
J Clin Oncol 21:4642-9. 2003..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...
Unrelated-donor cord blood transplantation for adult hematological malignanciesFederico Moscardo
Bone Marrow Transplant Unit, Hematology Department, Hospital Universitario La Fe, Valencia, Spain
Leuk Lymphoma 45:11-8. 2004..Current data confirm that UD-CBT is a reasonable alternative for those patients lacking a matched bone-marrow donor...
Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantationFederico Moscardo
Hematology Department, Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain
Exp Hematol 31:545-50. 2003..However, no comparative studies have been performed to investigate this. We analyzed the influence of selection for CD34(+) cells on the incidence and severity of hepatic veno-occlusive disease (VOD)...
Cord-blood transplantation in patients with leukemia--a real alternative for adultsMiguel A Sanz
N Engl J Med 351:2328-30. 2004
Basal CD34(+) cell count predicts peripheral blood progenitor cell mobilization and collection in healthy donors after administration of granulocyte colony-stimulating factorJavier de la Rubia
Haematologica 89:1530-2. 2004..Basal CD34(+) cell count and sex were the two variables that significantly predicted a better CD34(+) cell mobilization, and greater age was the only variable associated with lower CD34+ cell yields...
SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factorArmando V Mena-Duran
Inflammatory and Infectious Disease Center, The Burnham Institute, La Jolla, CA 92037, USA
Br J Haematol 129:791-4. 2005..0021) and had shorter survival (P < 0.001). Cox regression analysis demonstrated that SHP1 expression in megakaryocytes had prognostic relevance for time to progression (P = 0.009) and overall survival (P = 0.001)...
Viroporin activity of murine hepatitis virus E proteinVanessa Madan
Centro de Biologia Molecular CSIC UAM, Facultad de Ciencias, Universidad Autonoma, Cantoblanco, 28049 Madrid, Spain
FEBS Lett 579:3607-12. 2005..Finally, brefeldin A powerfully blocks the viroporin activity of the E protein in BHK cells, suggesting that an intact vesicular system is necessary for this coronavirus to permeabilize mammalian cells...
Analysis of factors associated with low peripheral blood progenitor cell collection in normal donorsJavier de la Rubia
Hematology Service, Hospital La Fe, Valencia, Spain
Transfusion 42:4-9. 2002..Predictive factors of the response to rHuG-CSF in normal donors have not been extensively studied...
[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]Blanca Xicoy
, , Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Med Clin (Barc) 126:41-6. 2006....
[Management of febrile neutropenic patients]Isidro Jarque
Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Espana
Enferm Infecc Microbiol Clin 23:24-9. 2005..In severe microbiologically documented infections, therapy should be maintained for a minimum of 14 days. Adjuvant therapy with granulopoiesis-stimulating factors is indicated in most patients...
The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemiaEva Barragan
Molecular Biology Laboratory, Dpt Medical Pathology, Spain
Leuk Res 31:947-53. 2007..05). This study suggests that the NQO1*2 polymorphism is relevant to the patient's response to induction therapy and that GST deletions influence treatment outcome after chemotherapy, especially in male patients...
The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemiaPascual Bolufer
Laboratory of Molecular Biology, Department of Medical Biopathology, Hospital Universitario La Fe, Valencia, Spain
Haematologica 92:308-14. 2007....
Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probesPascual Bolufer
Laboratorio de Biologia Molecular, Lab Hormonas, C Maternal Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain
Haematologica 87:23-32. 2002..The method is based on hybridization probe (HybProbe) chemistry applied in LightCycler equipment. The study group comprised 44 successive cases of pediatric acute lymphoblastic leukemia (P-ALL)...
Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantationMiguel A Diaz
Spanish Group for Allogeneic Peripheral Blood Stem Cell Transplantation
Haematologica 88:919-22. 2003..In this study we analyzed predictive factors for PBPC collection in pediatric donors...
